Data / Form D filings / Sorriso Pharmaceuticals, Inc.
Sorriso Pharmaceuticals, Inc.: Form D filing
Sorriso Pharmaceuticals, Inc., a biotechnology company in Sandy, UT, filed a Form D with the SEC in 2022. The latest, on January 11, 2022, reports $21.3 million sold of a $31.4 million offering to 11 investors.
Find out what Sorriso Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 6 NORTHRIDGE WAY, Sandy, UT, 84092
- Phone
- (619) 733-3852
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1903902
The full lists. Form D filings in Utah: 660 rows, $33, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 11, 2022 | New notice | $31,390,009 | $21,293,856 | $10,096,153 | 11 | Dec 21, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Brian Dorsey | Executive Officer | |
| Michael Grey | Director | |
| Edward Mathers | Director | |
| Ciara Kennedy, Ph.D. | Executive Officer, Director | |
| Mark Chin | Director | |
| Susan Dube | Executive Officer |
Other biotechnology companies in Utah that filed recently
- Life Impact Partners 14 LLC offering · Nov 9, 2026
- Life Impact Partners 15 LLC offering · Nov 9, 2026
- Life Impact Partners 7 LLC offering · Nov 6, 2026
- Life Impact Partners 6 LLC offering · Nov 6, 2026
- Life Impact Partners 3 LLC offering · Nov 6, 2026
- Life Impact Partners 5 LLC offering · Nov 6, 2026
- Life Impact Partners 4 LLC offering · Nov 6, 2026
- Life Impact Partners 2 LLC offering · Nov 6, 2026
- Life Impact Partners 8 LLC offering · Nov 6, 2026
- Life Impact Partners 1 LLC offering · Oct 22, 2026
- 3Helix, Inc. $7.8 million · Sep 21, 2026
- Halia Therapeutics, Inc. $3.5 million · Aug 31, 2026
- Paterna BioSciences HoldCo Inc. $6.3 million · Aug 12, 2026
Every Form D from the week of Jan 10, 2022 · All recent filings in Utah · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Sorriso Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.